|
A. OV 17-1
|
| |
HLA-A2
|
CEA
|
MUC-1
|
CD54
|
Calreticulin
|
CD95
|
Trail-R1
|
Trail-R2
|
| |
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
|
Control
|
99.4(34250)
|
40.7(731)
|
55.9(1170)
|
93.8(16581)
|
3.5(431)
|
57.2(691)
|
27.4(604)
|
10.1(93)
|
|
mL4-3 + L1-7(N)
|
99.1(34180)
|
40.0(872)
|
59.0(1124)
|
97.0(23584)
|
3.7(429)
|
65.3(813)
|
33.7(750)
|
10.1(107)
|
|
B. MDA-MB-231
|
| |
HLA-A2
|
CEA
|
MUC-1
|
CD54
|
Calreticulin
|
CD95
|
Trail-R1
|
Trail-R2
|
| |
% (MFI)
|
% (MFI)
|
%(MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
% (MFI)
|
|
Control
|
98.7(62083)
|
40.2(671)
|
56.0(2268)
|
97.9(30985)
|
10.6(377)
|
35.1(438)
|
44.0(775)
|
35.1(367)
|
|
mL4-3 + L1-7(N)
|
99.1(60495)
|
43.7(666)
|
59.4(2670)
|
99.1(35652)
|
15.9(428)
|
41.2(493)
|
48.7(797)
|
30.5(292)
|
- The human ovarian cancer cell line OV17-1 (A), and human breast cancer cell line MDA-MB-231 (B) were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respectively) or control (human IgG1-Fc at 26 μg/mL) for 3 days
- Cells were then harvested and analyzed by flow cytometry for expression of surface markers reported to be involved in CTL lysis (HLA-A2, CEA, MUC-1, ICAM-1, calreticulin, Fas, Trail-R1 and Trail-R2). Data indicate percentage of positive cells; MFI is in parentheses. Gating was performed using isotype controls Bold values indicate marker upregulation of > 10 % in percentage or MFI compared to controls
